Feeds › Insider trades
Insider trades
Open-market buys and sells by officers, directors and 10% owners, from SEC Form 4. Usually filed within two business days.
About this data
- What it is
- When a company's officers, directors or owners of more than 10% buy or sell its stock, they must report the trade to the SEC on Form 4. This feed shows purchases and sales on the open market; stock grants, option exercises and shares withheld for tax are left out.
- Who files it
- The insider, usually through the company, within two business days of the trade.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- Sales are often routine: insiders sell to diversify, to pay taxes, or under a 10b5-1 plan set up months in advance. A purchase with their own money is less common, which is why many investors pay closer attention to it.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Open-market trades per day, last 30 days
Purchases Sales
By trade date. Insiders have two business days to file, so the most recent days fill in later.
Latest open-market insider trades
Showing: ticker NAMS
| Traded | Insider | Company | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 14, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Buy | 10,000 | $22.65 | $226.5K Buy | Form 4 ↗ |
| Sep 4, 2026 | John W. Smither Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 1,600 | $25.32 | $40.5K Sale | Form 4 ↗ |
| Aug 24, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 125,000 | $26.91 | $3.4M Sale | Form 4 ↗ |
| Jul 20, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 2,915 | $31.71 | $92.4K Sale | Form 4 ↗ |
| Jul 20, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 31,885 | $31.05 | $990.0K Sale | Form 4 ↗ |
| Jul 20, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 70,200 | $29.96 | $2.1M Sale | Form 4 ↗ |
| Jun 22, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 300 | $30.73 | $9,219 Sale | Form 4 ↗ |
| Jun 22, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 39,700 | $30.20 | $1.2M Sale | Form 4 ↗ |
| May 26, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 65,000 | $35.69 | $2.3M Sale | Form 4 ↗ |
| Mar 11, 2026 | Louis G. Lange Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 446 | $31.23 | $13.9K Sale | Form 4 ↗ |
| Mar 11, 2026 | Louis G. Lange Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 44,173 | $30.41 | $1.3M Sale | Form 4 ↗ |
| Mar 9, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 101,409 | $30.29 | $3.1M Sale | Form 4 ↗ |
| Mar 6, 2026 | Louis G. Lange Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 28,186 | $29.41 | $829.0K Sale | Form 4 ↗ |
| Mar 6, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 94,124 | $30.32 | $2.9M Sale | Form 4 ↗ |
| Mar 5, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 104,467 | $30.30 | $3.2M Sale | Form 4 ↗ |
| Mar 2, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 443,707 | $33.25 | $14.8M Sale | Form 4 ↗ |
| Feb 26, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 17,924 | $34.44 | $617.3K Sale | Form 4 ↗ |
| Feb 26, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 165,408 | $33.63 | $5.6M Sale | Form 4 ↗ |
| Feb 25, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 1,300 | $36.68 | $47.7K Sale | Form 4 ↗ |
| Feb 25, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 10,436 | $35.96 | $375.3K Sale | Form 4 ↗ |
| Feb 25, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 46,517 | $35.11 | $1.6M Sale | Form 4 ↗ |
| Feb 24, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 3,161 | $36.46 | $115.3K Sale | Form 4 ↗ |
| Feb 24, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 61,547 | $36.13 | $2.2M Sale | Form 4 ↗ |
| Feb 20, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 30,789 | $35.46 | $1.1M Sale | Form 4 ↗ |
| Feb 20, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 14,692 | $35.00 | $514.2K Sale | Form 4 ↗ |
| Jan 28, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 32,612 | $31.80 | $1.0M Sale | Form 4 ↗ |
| Jan 27, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 39,816 | $32.62 | $1.3M Sale | Form 4 ↗ |
| Jan 26, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 309 | $33.45 | $10.3K Sale | Form 4 ↗ |
| Jan 26, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 34,091 | $32.77 | $1.1M Sale | Form 4 ↗ |
| Jan 23, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 12,767 | $34.37 | $438.8K Sale | Form 4 ↗ |
| Jan 23, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 25,405 | $33.44 | $849.5K Sale | Form 4 ↗ |
| Jan 21, 2026 | Mayur Ian Somaiya Chief Financial Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 24,362 | $33.80 | $823.4K Sale | Form 4 ↗ |
| Jan 21, 2026 | Mayur Ian Somaiya Chief Financial Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 15,422 | $33.25 | $512.8K Sale | Form 4 ↗ |
| Jan 20, 2026 | Mayur Ian Somaiya Chief Financial Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 19,604 | $32.38 | $634.8K Sale | Form 4 ↗ |
| Jan 20, 2026 | Mayur Ian Somaiya Chief Financial Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 39,712 | $31.78 | $1.3M Sale | Form 4 ↗ |
| Jan 20, 2026 | Mayur Ian Somaiya Chief Financial Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 900 | $30.64 | $27.6K Sale | Form 4 ↗ |
| Jan 7, 2026 | Michael H. Davidson Chief Executive Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 11,582 | — | — Sale | Form 4 ↗ |
| Jan 5, 2026 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 6,000 | $33.25 | $199.5K Sale | Form 4 ↗ |
| Jan 5, 2026 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 2,647 | $33.25 | $88.0K Sale | Form 4 ↗ |
| Jan 5, 2026 | Mayur Ian Somaiya Chief Financial Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 5,118 | $33.25 | $170.2K Sale | Form 4 ↗ |
| Dec 26, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 43,872 | $35.30 | $1.5M Sale | Form 4 ↗ |
| Dec 24, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 26,011 | $35.68 | $928.1K Sale | Form 4 ↗ |
| Dec 23, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 75,117 | $36.21 | $2.7M Sale | Form 4 ↗ |
| Sep 15, 2025 | James N. Topper Director | NAMS NewAmsterdam Pharma Company N.V. | Buy | 660 | $23.70 | $15.6K Buy | Form 4 ↗ |
| Sep 9, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 96,896 | $26.11 | $2.5M Sale | Form 4 ↗ |
| Sep 9, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 53,104 | $25.31 | $1.3M Sale | Form 4 ↗ |
| Sep 8, 2025 | James N. Topper Director | NAMS NewAmsterdam Pharma Company N.V. | Buy | 1,260 | $24.99 | $31.5K Buy | Form 4 ↗ |
| Sep 3, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 18,073 | $25.09 | $453.5K Sale | Form 4 ↗ |
| Aug 25, 2025 | Louise Frederika Kooij Chief Accounting Officer | NAMS NewAmsterdam Pharma Company N.V. | Sale | 8,269 | $24.86 | $205.6K Sale | Form 4 ↗ |
| Aug 22, 2025 | Jacob Pieter Kastelein Johannes Chief Scientific Officer, Director | NAMS NewAmsterdam Pharma Company N.V. | Sale | 7,658 | $25.49 | $195.2K Sale | Form 4 ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 6:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances